

# An open-label pilot study on the effects of trivalent inactivated influenza vaccination (Influvac®) in patients with hypo- and dysgammaglobulinemia.

No registrations found.

|                              |                     |
|------------------------------|---------------------|
| <b>Ethical review</b>        | Positive opinion    |
| <b>Status</b>                | Recruitment stopped |
| <b>Health condition type</b> | -                   |
| <b>Study type</b>            | Interventional      |

## Summary

### ID

NL-OMON23525

### Source

NTR

### Brief title

VIPID

### Health condition

patients with hypo- or dysgammaglobulinemia fulfilling the criteria for primary immunodeficiency as defined by the Pan-American Group for Immunodeficiency and the European Society for immunodeficiencies

## Sponsors and support

**Primary sponsor:** None

**Source(s) of monetary or material Support:** Grant applications are under construction

## Intervention

## Outcome measures

### Primary outcome

Cellular immune responses.

## **Secondary outcome**

1. Humoral immune responses;
2. Side effects.

## **Study description**

### **Background summary**

Hypo- or dysgammaglobulinemia, caused by several primary immunodeficiency syndromes, usually leads to recurrent infections. Vaccination to prevent these infections in general does not result in an adequate generation of protective antibodies in this category of patients. However, for prevention of influenza virus infection, besides protective antibodies T-cell responses have been shown to prevent this infection or to reduce the severity of influenza virus infection.

Although in a number of the primary immunodeficiency syndromes causing hypo- or dysgammaglobulinemia B-cell dysfunction may be accompanied by reduced T-cell responses, and treatment with intravenous immunoglobulins alters cellular immunity, no studies have been performed on vaccination against influenza with the currently used subunit vaccines in this category of patients.

In this context, of patients unable to produce protective antibodies, but possibly capable of eliciting protective T-cell responses to influenza virus, we designed a study protocol to determine the cellular immune response following influenza vaccination in patients with hypo- or dysgammaglobulinemia and to determine the usefulness of administering influenza vaccine to this category of patients.

Humoral and T-cell responses will be determined by several proven methods in patients with hypo- or dysgammaglobulinemia at three time points following vaccination with influenza virus subunit vaccine for the season 2006-2007, and compared with the responses measured in healthy controls. A number of 50 patients and 50 matched healthy controls will be included. Patients will be stratified according to the treatment with intravenous immunoglobulins. The two questions to be answered are:

1. Is vaccination with trivalent inactivated influenza vaccine in hypo- and dysgammaglobulinemic patients useful; elicit these patients adequate T-cell responses after influenza vaccination?
2. Is the cellular response dependent on IVIG substitution therapy?

## Study objective

Patients with hypo- or dysgammaglobulinemia have comparable cellular immun responses to influenza vaccin as matched healthy volunteers.

## Study design

N/A

## Intervention

Vaccination with trivalent inactivated influenza vaccin (Influvac®).

## Contacts

### Public

University Medical Center Groningen (UMCG),  
Department of Internal Medicine  
P.O. Box 30001  
S. Assen, van  
Groningen 9700 RB  
The Netherlands

### Scientific

University Medical Center Groningen (UMCG),  
Department of Internal Medicine  
P.O. Box 30001  
S. Assen, van  
Groningen 9700 RB  
The Netherlands

## Eligibility criteria

### Inclusion criteria

1. Patients have to fulfil the diagnostic criteria for primary immunodeficiency as defined by the Pan-American Group for Immunodeficiency and the European Society for immunodeficiencies;
2. Informed consent.

## Exclusion criteria

1. Age under 18 years;
2. Current infection, defined as fever in combination with clinical focal signs of infection and the need for therapeutic antibiotic treatment;
3. Pregnancy;
4. Malignancy;
5. Continuous use of immunosuppressive drugs;
6. Known allergy to any substance of Influvac®.

## Study design

### Design

|                     |                         |
|---------------------|-------------------------|
| Study type:         | Interventional          |
| Intervention model: | Other                   |
| Masking:            | Open (masking not used) |
| Control:            | Active                  |

### Recruitment

|                           |                     |
|---------------------------|---------------------|
| NL                        |                     |
| Recruitment status:       | Recruitment stopped |
| Start date (anticipated): | 01-10-2006          |
| Enrollment:               | 100                 |
| Type:                     | Actual              |

## Ethics review

|                   |                  |
|-------------------|------------------|
| Positive opinion  |                  |
| Date:             | 08-09-2006       |
| Application type: | First submission |

## Study registrations

### Followed up by the following (possibly more current) registration

No registrations found.

### Other (possibly less up-to-date) registrations in this register

No registrations found.

### In other registers

| <b>Register</b> | <b>ID</b>      |
|-----------------|----------------|
| NTR-new         | NL756          |
| NTR-old         | NTR767         |
| Other           | : N/A          |
| ISRCTN          | ISRCTN31814323 |

## Study results

### Summary results

N/A